Advances in the Treatment of Renal Cell Carcinoma
This Special Issue of Cancers focuses on new advances in the treatment of renal cell carcinoma, both surgical and pharmacological (and combinations of these), and novel approaches to tackle treatment resistance and improve our understanding of this phenomenon.
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Book Chapter |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 02794naaaa2200805uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_79585 | ||
| 005 | 20220321 | ||
| 020 | |a books978-3-0365-2934-9 | ||
| 020 | |a 9783036529356 | ||
| 020 | |a 9783036529349 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-2934-9 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Reynolds, Paul |4 edt | |
| 700 | 1 | |a Stewart, Grant D |4 edt | |
| 700 | 1 | |a Reynolds, Paul |4 oth | |
| 700 | 1 | |a Stewart, Grant D |4 oth | |
| 245 | 1 | 0 | |a Advances in the Treatment of Renal Cell Carcinoma |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (221 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This Special Issue of Cancers focuses on new advances in the treatment of renal cell carcinoma, both surgical and pharmacological (and combinations of these), and novel approaches to tackle treatment resistance and improve our understanding of this phenomenon. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a renal cell carcinoma | ||
| 653 | |a autophagy | ||
| 653 | |a hydroxychloroquine | ||
| 653 | |a chloroquine | ||
| 653 | |a ROC-325 | ||
| 653 | |a cysteine cathepsins | ||
| 653 | |a cysteine cathepsin inhibitors | ||
| 653 | |a lysosome | ||
| 653 | |a renal cancer | ||
| 653 | |a metastatic renal cell carcinoma | ||
| 653 | |a immune-based combination therapies | ||
| 653 | |a network meta-analysis | ||
| 653 | |a PD-L1 | ||
| 653 | |a predictive | ||
| 653 | |a biomarker | ||
| 653 | |a treatment | ||
| 653 | |a TKIs | ||
| 653 | |a mRCC | ||
| 653 | |a biomarkers | ||
| 653 | |a soluble factors | ||
| 653 | |a immunotherapy | ||
| 653 | |a renal cell carcinoma (RCC) | ||
| 653 | |a sunitib resistance | ||
| 653 | |a artesunate (ART) | ||
| 653 | |a Traditional Chinese Medicine (TCM) | ||
| 653 | |a growth inhibition | ||
| 653 | |a ferroptosis | ||
| 653 | |a reactive oxygen species (ROS) | ||
| 653 | |a clear cell renal cell carcinoma | ||
| 653 | |a ccRCC | ||
| 653 | |a RCC | ||
| 653 | |a kidney cancer | ||
| 653 | |a evolution | ||
| 653 | |a evolutionary trajectory | ||
| 653 | |a metastatic | ||
| 653 | |a second line therapy | ||
| 653 | |a renal cell cancer | ||
| 653 | |a immune checkpoint inhibitors | ||
| 653 | |a tyrosine kinase inhibitors | ||
| 653 | |a individualization | ||
| 653 | |a genomic signature | ||
| 653 | |a transcriptomic analysis | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4966 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/79585 |7 0 |z DOAB: description of the publication |